Drug Company X reports the introduction of a new pill that is guaranteed to cause weight loss with no side effects. The information was advertised in connection with a public offering of stock of the company's stock. Later, it becomes apparent through additional testing that unfortunately the new pill also results in premature hair loss, a material issue. Monika is the president of Company X and
is very pleased with sales of the drug. She recognizes that she can no longer advertise the drug as having no side effects, but she does not believe she has made any misrepresentations because she was not aware of the hair loss side effect when previous statements were made. She decides to do nothing. Has she made the correct decision as far as Rule 10b-5 is concerned?
a. Yes, because she has no duty to disclose later test results.
b. Yes, because she has no duty to disclose later test results that involve only cosmetic issues.
c. Yes, because she has no duty to disclose later test results that involve issues that are not life threatening.
d. No, she made the wrong decision because she has an obligation to disclose the results.
d
You might also like to view...
Letters should be _______________
a. at least one page long b. written by one person c. personal and convincing d. hand delivered
Agencies employing informal rulemaking rely primarily on:
a. oral testimony by interested parties b. written testimony by interested parties c. research conducted by the agency itself with no other input d. research conducted by the Congress with no other input
Delivery is one of the PMBOK process groups
Indicate whether the statement is true or false
The stakeholder capitalism model does not assume that equity markets are either efficient or inefficient
Indicate whether the statement is true or false.